What's Next: Rhythm Pharmaceuticals's Earnings Preview

Rhythm Pharmaceuticals (NASDAQ:RYTM) will release its quarterly earnings report on Tuesday, 2024-11-05. Here's a brief overview for investors ahead of the announcement.

Analysts anticipate Rhythm Pharmaceuticals to report an earnings per share (EPS) of $-0.81.

The announcement from Rhythm Pharmaceuticals is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.

It's worth noting for new investors that guidance can be a key determinant of stock price movements.

Past Earnings Performance

The company's EPS beat by $0.16 in the last quarter, leading to a 1.09% drop in the share price on the following day.

Here's a look at Rhythm Pharmaceuticals's past performance and the resulting price change:

Quarter

Q2 2024

Q1 2024

Q4 2023

Q3 2023

EPS Estimate

-0.71

-2.16

-0.7

-0.76

EPS Actual

-0.55

-2.35

-0.7

-0.76

Price Change %

-1.0%

-1.0%

2.0%

2.0%

Stock Performance

Shares of Rhythm Pharmaceuticals were trading at $49.01 as of November 01. Over the last 52-week period, shares are up 94.77%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

Analysts' Take on Rhythm Pharmaceuticals

For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Rhythm Pharmaceuticals.

With 8 analyst ratings, Rhythm Pharmaceuticals has a consensus rating of Buy. The average one-year price target is $61.0, indicating a potential 24.46% upside.

Peer Ratings Comparison

The below comparison of the analyst ratings and average 1-year price targets of Iovance Biotherapeutics, Amicus ...